TILT Holdings Past Earnings Performance
Past criteria checks 0/6
TILT Holdings has been growing earnings at an average annual rate of 53.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 16.3% per year.
Key information
53.5%
Earnings growth rate
88.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 16.3% |
| Return on equity | -102.3% |
| Net Margin | -37.6% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How TILT Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 166 | -62 | 38 | 0 |
| 30 Sep 23 | 173 | -114 | 42 | 0 |
| 30 Jun 23 | 169 | -121 | 44 | 0 |
| 31 Mar 23 | 174 | -101 | 49 | 0 |
| 31 Dec 22 | 174 | -107 | 49 | 0 |
| 30 Sep 22 | 184 | -54 | 47 | 0 |
| 30 Jun 22 | 197 | -38 | 47 | 0 |
| 31 Mar 22 | 198 | -30 | 44 | 0 |
| 31 Dec 21 | 203 | -35 | 42 | 0 |
| 30 Sep 21 | 191 | -60 | 43 | 0 |
| 30 Jun 21 | 177 | -63 | 40 | 0 |
| 31 Mar 21 | 165 | -73 | 40 | 0 |
| 31 Dec 20 | 158 | -52 | 40 | 0 |
| 30 Sep 20 | 144 | -28 | 33 | 0 |
| 30 Jun 20 | 151 | 0 | 0 | 0 |
| 31 Mar 20 | 153 | -40 | 55 | 0 |
| 31 Dec 19 | 147 | -122 | 122 | 0 |
| 30 Sep 19 | 122 | -638 | 153 | 0 |
| 30 Jun 19 | 77 | -671 | 185 | 0 |
| 31 Mar 19 | 38 | -626 | 126 | 0 |
| 31 Dec 18 | 4 | -550 | 52 | 0 |
Quality Earnings: 0T01 is currently unprofitable.
Growing Profit Margin: 0T01 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0T01 is unprofitable, but has reduced losses over the past 5 years at a rate of 53.5% per year.
Accelerating Growth: Unable to compare 0T01's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0T01 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 0T01 has a negative Return on Equity (-102.28%), as it is currently unprofitable.